Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Open-label, follow-up study for subjects who completed the EPITOPE study.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • biological: DBV712 250 mcg

Eligibility


Inclusion Criteria:

   - completion of the EPITOPE study

Exclusion Criteria:

   - Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled
   generalized active eczema, ichthyosis vulgaris) extending widely on the skin and
   especially on the back or arms with no intact zones to apply the Viaskin patches.

   - Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma

Ages Eligible for Study

2 Years - 5 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting